[Basic study of XXXX transporter imaging with 131I-beta-CIT].

@entity5212 @entity304 @entity935 @entity191 @entity1726 @entity468
beta-CIT was labeled with 131I by the peracetic acid method. Cat model of @entity304 was set up with @entity5212 . Each of normal and @entity1726 model @entity468 was given an injection of 74 MBq/0.5 ml 131I-beta-CIT into the femur vein. Then the blood samples were obtained at 4 h and 20 h, the radioactivity was counted with calibrator. The biodistribution data of 131I-beta-CIT in cat body was calculated (ID%/g). The @entity468 were subjected to imaging at 0.5 h, 1 h, 2 h, 4 h, 20 h after the administration of radiopharmaceutical. The radioactivity in striatum and cerebellum was measured and striatal specific binding ratios were calculated. The Results showed that the radio chemical purity of 131I-beta-CIT was 97.62% +/- 0.31%. The 131I-beta-CIT remained stable for at least 4 h after incubation with water and serum respectively. Following intravenous administration in @entity468 , 131I-beta-CIT showed high accumulation in striatum. The study of imaging in @entity468 showed that striatal specific uptake of 131I-beta-CIT at 20 h after injection was 4.83 +/- 0.82 in normal @entity468 and 2.92 +/- 0.66 in @entity1726 @entity468 . There was a significant reduction of striatal tracer uptake in @entity1726 @entity468 , compared to the controls. The results of biodistribution study was in agreement with the results of imaging study. These results suggest that beta-CIT is an ideal agent for @entity935 transporter imaging and can be used for the diagnosis of @entity191 .
